JPWO2021187615A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021187615A5 JPWO2021187615A5 JP2022548860A JP2022548860A JPWO2021187615A5 JP WO2021187615 A5 JPWO2021187615 A5 JP WO2021187615A5 JP 2022548860 A JP2022548860 A JP 2022548860A JP 2022548860 A JP2022548860 A JP 2022548860A JP WO2021187615 A5 JPWO2021187615 A5 JP WO2021187615A5
- Authority
- JP
- Japan
- Prior art keywords
- marker
- chemokine
- cxcl11
- cxcl9
- cxcl10
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 17
- 102000019034 Chemokines Human genes 0.000 claims 8
- 108010012236 Chemokines Proteins 0.000 claims 8
- 239000003550 marker Substances 0.000 claims 8
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims 4
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 claims 4
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 claims 4
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 claims 4
- 101000858060 Homo sapiens C-X-C motif chemokine 11 Proteins 0.000 claims 4
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 102100035294 Chemokine XC receptor 1 Human genes 0.000 claims 3
- 101000804783 Homo sapiens Chemokine XC receptor 1 Proteins 0.000 claims 3
- 108020004999 messenger RNA Proteins 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 2
- 210000004443 dendritic cell Anatomy 0.000 claims 2
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 101150014003 Batf3 gene Proteins 0.000 claims 1
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 claims 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 claims 1
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 claims 1
- 239000012269 PD-1/PD-L1 inhibitor Substances 0.000 claims 1
- 230000006044 T cell activation Effects 0.000 claims 1
- 229960003852 atezolizumab Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 210000003162 effector t lymphocyte Anatomy 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 229940121653 pd-1/pd-l1 inhibitor Drugs 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Claims (14)
患者に由来する試料中の以下の(i)および(ii)を検出する段階:
(i)CD8陽性T細胞に対してクロスプレゼンテーション能力を有する樹状細胞(DC)の、腫瘍内の量を推定するための、少なくとも1つのマーカー;および
(ii)腫瘍内でエフェクターT細胞を集積させる、少なくとも1つのケモカイン。 PD-1/PD-L1 inhibition in patients having or suspected of having cancer that is responsive to a therapy comprising administration of an effective amount of a PD-1/PD-L1 inhibitor. A method of predicting the therapeutic effect of an agent , the method comprising the steps of:
Detecting (i) and (ii) of the following in a sample derived from a patient:
(i) at least one marker for estimating the amount within the tumor of dendritic cells (DC) capable of cross-presenting to CD8+ T cells; and
(ii) at least one chemokine that recruits effector T cells within the tumor;
(ii)を検出する段階が、ケモカインのmRNA発現レベルを測定することである、
請求項1～10のいずれか一項記載の方法。 The step of detecting (i) is to measure the mRNA expression level of the marker,
(ii) the step of detecting is measuring the mRNA expression level of the chemokine;
The method according to any one of claims 1 to 10.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020048845 | 2020-03-19 | ||
| JP2020048845 | 2020-03-19 | ||
| PCT/JP2021/011302 WO2021187615A1 (en) | 2020-03-19 | 2021-03-19 | Biomarkers for predicting the response to checkpoint inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023517487A JP2023517487A (en) | 2023-04-26 |
| JPWO2021187615A5 true JPWO2021187615A5 (en) | 2024-02-29 |
Family
ID=77768173
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022548860A Pending JP2023517487A (en) | 2020-03-19 | 2021-03-19 | Biomarkers for predicting response to checkpoint inhibitors |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230146730A1 (en) |
| EP (1) | EP4121769A4 (en) |
| JP (1) | JP2023517487A (en) |
| KR (1) | KR20220156855A (en) |
| CN (1) | CN115485559A (en) |
| AU (1) | AU2021239667A1 (en) |
| CA (1) | CA3168951A1 (en) |
| IL (1) | IL296431A (en) |
| MX (1) | MX2022011068A (en) |
| TW (1) | TW202140568A (en) |
| WO (1) | WO2021187615A1 (en) |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR095363A1 (en) | 2013-03-15 | 2015-10-14 | Genentech Inc | BIOMARKERS AND METHODS FOR THE TREATMENT OF CONDITIONS RELATED TO PD-1 AND PD-L1 |
| WO2015120382A1 (en) | 2014-02-07 | 2015-08-13 | The Johns Hopkins University | Predicting response to epigenetic drug therapy |
| US11326211B2 (en) | 2015-04-17 | 2022-05-10 | Merck Sharp & Dohme Corp. | Blood-based biomarkers of tumor sensitivity to PD-1 antagonists |
| GB201512869D0 (en) | 2015-07-21 | 2015-09-02 | Almac Diagnostics Ltd | Gene signature for minute therapies |
| JP7034080B2 (en) * | 2016-02-25 | 2022-03-11 | メモリアル スローン ケタリング キャンサー センター | Recombinant MVA or MVAΔE3L expressing human FLT3L and their use as immunotherapeutic agents against solid tumors |
| WO2017176925A1 (en) | 2016-04-05 | 2017-10-12 | Bristol-Myers Squibb Company | Cytokine profiling analysis for predicting prognosis of a patient in need of an anti-cancer treatment |
| WO2017190074A1 (en) * | 2016-04-28 | 2017-11-02 | The University Of Chicago | Lymphangiogenesis for therapeutic immunomodulation |
| EP3516396B1 (en) | 2016-09-26 | 2024-11-13 | F. Hoffmann-La Roche AG | Predicting response to pd-1 axis inhibitors |
| MX2019012192A (en) * | 2017-04-14 | 2020-01-21 | Genentech Inc | Diagnostic and therapeutic methods for cancer. |
| WO2018209324A2 (en) | 2017-05-11 | 2018-11-15 | The Broad Institute, Inc. | Methods and compositions of use of cd8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof |
| CA3066054A1 (en) | 2017-06-04 | 2018-12-13 | Rappaport Family Institute For Research In The Medical Sciences | Method of predicting personalized response to cancer therapy and kit therefor |
| GB202209539D0 (en) | 2017-06-13 | 2022-08-10 | Bostongene Corp | Systems and methods for identifying cancer treatments from normalized biomarker scores |
| CA3105988A1 (en) * | 2018-07-11 | 2020-01-16 | Abhishek Datta | High-affinity, isoform-selective tgf.beta.1 inhibitors and use thereof |
-
2021
- 2021-03-19 WO PCT/JP2021/011302 patent/WO2021187615A1/en unknown
- 2021-03-19 EP EP21770468.3A patent/EP4121769A4/en active Pending
- 2021-03-19 KR KR1020227035174A patent/KR20220156855A/en unknown
- 2021-03-19 TW TW110109958A patent/TW202140568A/en unknown
- 2021-03-19 CA CA3168951A patent/CA3168951A1/en active Pending
- 2021-03-19 MX MX2022011068A patent/MX2022011068A/en unknown
- 2021-03-19 AU AU2021239667A patent/AU2021239667A1/en active Pending
- 2021-03-19 US US17/912,257 patent/US20230146730A1/en active Pending
- 2021-03-19 IL IL296431A patent/IL296431A/en unknown
- 2021-03-19 CN CN202180028341.8A patent/CN115485559A/en active Pending
- 2021-03-19 JP JP2022548860A patent/JP2023517487A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3639169B1 (en) | Systems and methods for generating, visualizing and classifying molecular functional profiles | |
| Ballman et al. | The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme | |
| Lu et al. | The T-cell chemokine receptor CXCR3 is expressed highly in low-grade mycosis fungoides | |
| Kuefner et al. | Effect of CT scan protocols on x-ray-induced DNA double-strand breaks in blood lymphocytes of patients undergoing coronary CT angiography | |
| Gressin et al. | A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma | |
| Caldarella et al. | The role of fluorine-18-fluorodeoxyglucose positron emission tomography in evaluating the response to tyrosine-kinase inhibitors in patients with metastatic primary renal cell carcinoma | |
| Igarashi et al. | Clinical significance of inter-arm pressure difference and ankle-brachial pressure index in patients with suspected coronary artery disease | |
| US20230392215A1 (en) | Biomarkers for cancer immunotherapy outcomes | |
| Puente et al. | Influence of sustained viral response on the regression of fibrosis and portal hypertension in cirrhotic HCV patients treated with antiviral triple therapy | |
| US20110077215A1 (en) | DNA Methylation As A Target For Diagnosis And Treatment Of Chronic Lymphocytic Leukema (CLL) | |
| Bersanelli et al. | Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: the multicenter retrospective CLARITY study | |
| Kuipers et al. | Predicting Radiation-Induced Lung Injury in Patients With Lung Cancer: Challenges and Opportunities | |
| US20230235408A1 (en) | Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapies | |
| JPWO2021187615A5 (en) | ||
| Deviller et al. | Guanyl cyclase activity of human blood lymphocytes | |
| Deac et al. | 5-fluorouracil therapeutic drug monitoring and adverse events in a Romanian population | |
| Dobrolinska et al. | The prognostic value of visual and automatic coronary calcium scoring from low-dose computed tomography-[15O]-water positron emission tomography | |
| Rosner et al. | Glomerular filtration rate measurement and chemotherapy dosing | |
| Müller et al. | Improved flow‐cytometric detection of low P‐glycoprotein expression in leukaemic blasts by histogram subtraction analysis | |
| Bian et al. | Systemic blood predictors of elevated pulmonary artery pressure assessed by non-invasive echocardiography after acute exposure to high altitude: A prospective cohort study | |
| Liu et al. | An On‐Treatment Decreased Trend of Serum IL‐6 and IL‐8 as Predictive Markers Quickly Reflects Short‐Term Efficacy of PD‐1 Blockade Immunochemotherapy in Patients with Advanced Gastric Cancer | |
| CN114354943A (en) | Immune therapy efficacy prediction marker and prediction model construction and application | |
| Al-Nadaf et al. | Population pharmacokinetics identifies rapid gastrointestinal absorption and plasma clearance of oral chlorambucil administered to cats with indolent lymphoproliferative malignancies | |
| Araki et al. | Serum immunosuppressive acidic protein doubling time as a prognostic factor for recurrent renal cell carcinoma after nephrectomy | |
| Rapoport et al. | Prognostic significance of neutrophil/lymphocyte ratio in patients undergoing treatment with nivolumab for recurrent non-small cell lung cancer |